Showing 1501-1510 of 2527 results for "".
- Introducing Juvéderm It, Allergan's Newest Ad Campaignhttps://modernaesthetics.com/news/introducing-juvderm-it-allergans-newest-ad-campaign/2472020/Allergan plc is rolling out a new Juvéderm advertising campaign that aims to make this family of fillers a household name. Comprising a modernized logo, a bright, poppy color scheme, an edgy soundtrack and robust social media component, Juvéderm It is the first new adv
- Recros Medica Unveils the Nuvellus Brand for Its Novel Rotational Fractional Resection Technologyhttps://modernaesthetics.com/news/recros-medica-unveils-the-nuvellus-brand-for-its-novel-rotational-fractional-resection-technology/2472023/Recros Medica, Inc. is unveiling the Nuvellus brand at this week’s American Society of Plastic Surgery meeting. The company will display at booth #1264, where it will introduce Nuvellus as an innovative, minimally-invasive surgical procedure in develop
- RealSelf: One in Three U.S. Adults are Considering Nips/Tuckshttps://modernaesthetics.com/news/realself-one-in-three-us-adults-are-considering-nipstucks/2472025/One in three adults (37 percent) in the U.S. are considering at least one cosmetic treatment in the next 12 months, with significantly more considering nonsurgical procedures (34 percent) than surgical ones (24 percent), according to the
- New Cutera Survey Results Help Define Body Contouring Markethttps://modernaesthetics.com/news/new-cutera-survey-helps-define-body-contouring-market/2472026/One third of Americans opt for body sculpting treatments to look better naked, according to a new survey from Cutera, Inc. The survey results we
- Nestle to Explore Strategic Options for Skin Health Divisionhttps://modernaesthetics.com/news/nestle-to-explore-strategic-options-for-skin-health-division/2472031/...After further analysis and consideration, the Board has come to the conclusion that the future growth opportunities of Nestlé Skin Health lie increasingly outside the Group’s strategic scope
- New for EBD-Based Acne Care: Sebacia Microparticles Clearedhttps://modernaesthetics.com/news/new-for-ebd-based-acne-care-sebacia-microparticles-cleared/2472033/Sebacia Microparticles are now FDA-cleared for use in the treatment of acne. The clearance comes on the heels of a pivotal study demonstrating the clinical safety and efficacy of the micoparticles. Sebacia, Inc. had submitted its 510(k) submission to the FDA in June 2018. Sebacia Mic
- New Laser Handpiece Clears Green, Blue, and Purple Tattoos in Fewer Treatmentshttps://modernaesthetics.com/news/new-laser-handpiece-clears-green-blue-and-purple-tattoos-in-fewer-treatments/2472037/A new titanium sapphire laser handpiece can clear green, blue, and purple tattoo pigments in fewer treatments, according to a
- New Guidelines Seek to Rein in Inappropriate Teen Plastic Surgerieshttps://modernaesthetics.com/news/new-guidelines-seek-to-rein-in-inappropriate-teen-plastic-surgeries/2472045/New teen plastic surgery guidelines call for age consideration, parental consent and other measures to improve upon the safety of these procedures. The guidelines are published in the September issue of Plastic and Reconstr
- Cynosure to Distribute Porter Instrument's Nitrous Oxide and Oxygen System in Aesthetics Markethttps://modernaesthetics.com/news/cynosure-to-distribute-porter-instruments-nitrous-oxide-and-oxygen-system-in-aesthetics-market/2472047/Hologic, Inc.'s Cynosure division has penned a deal with Porter Instrument, a business unit of Parker Hannifin Corporation, for distribution rights in the United States and Canada to Porter Instrument&#
- Bonti's Novel Neurotoxin Shows Promise in Early Study of Scar Reduction After Mohs Surgeryhttps://modernaesthetics.com/news/bontis-novel-neurotoxin-shows-promise-in-early-study-of-scar-reduction-after-mohs-surgery/2472052/Topline results from Bonti’s SHINE-1 Phase 2a clinical trial suggest that its novel neurotoxin is safe and likely effective for scar reduction following Mohs surgery. EB-001, the active ingredient in EB-001A, is a novel botulinum neurotoxin serotype E (BoNT/E) with a unique clinical